Dark

Check out our Dark Pool Levels

CYT
Cyteir Therapeutics, Inc. Common Stock
stock NASDAQ

Inactive

May 23, 2025

30.26USD-1.976%(-0.61)200

Pre-market

0.00USD-100.000%(-30.87)0

After-hours

0.00USD0.000%(0.00)0

Overview HistoricalExchangesShortsNews

Jan 12, 2022

07:34AM EST Cyteir Says First Patient Dosed In Phase 1 Combination Trial With CYT-0851 On Hematologic Malignancies And Solid Tumors RTTNews

07:31AM EST Cyteir Therapeutics Announces First Patient Dosed In Phase 1 Combination Trial With CYT-0851 Benzinga

Jan 3, 2022

07:30AM EST Cyteir Therapeutics to Participate in the 40th Annual J.P. Morgan Healthcare Conference Business Wire

Dec 16, 2021

07:34AM EST Cyteir Therapeutics Appoints Jeffrey Humphrey To Board RTTNews

07:30AM EST Cyteir Therapeutics Announces the Appointment of Dr. Jeffrey S. Humphrey to Board of Directors Business Wire

Nov 19, 2021

08:42AM EST 08:42 Friday, November 19, 2021Wedbush (RTTNews) - Wedbush Reiterates Cyteir Therapeutics, Inc. (CYT) At Outperform With $40 Price Target RTTNews

Nov 12, 2021

07:45AM EST Cyteir Therapeutics Q3 EPS $(0.33) Up From $(3.44) YoY Benzinga

07:34AM EST Cyteir Therapeutics Q3 Net Loss $11.7 Mln Or $0.33/Shr Vs Loss $5.0 Mln Or $3.44/Shr Last Year RTTNews

07:30AM EST Cyteir Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Highlights Business Wire

Nov 1, 2021

07:30AM EDT Cyteir Therapeutics to Participate in the Credit Suisse 30th Annual Healthcare Conference Business Wire

Sep 20, 2021

07:40AM EDT Cyteir Therapeutics Selected to Join Russell 2000 Index Benzinga

Sep 14, 2021

07:01AM EDT Lightstone Ventures Raises $375 Million Fund PR Newswire

Sep 1, 2021

07:30AM EDT Cyteir Therapeutics to Participate in the 19th Annual Morgan Stanley Global Healthcare Conference Business Wire

Aug 9, 2021

05:26PM EDT Cyteir Therapeutics Q2 EPS $(4.83) Down From $(3.18) YoY Benzinga

04:15PM EDT Cyteir Therapeutics Q2 Loss/share $4.83 Vs. Loss $3.18 Year Ago RTTNews

04:05PM EDT Cyteir Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Highlights Business Wire

Aug 2, 2021

07:30AM EDT Cyteir Therapeutics to Participate in the 2021 Wedbush PacGrow Healthcare Conference Business Wire

Jul 22, 2021

11:34AM EDT The Daily Biotech Pulse: FDA Nod For Merck-Eisai, Seres' Ulcerative Colitis Drug Flunks Midstage Study, Pfizer To Invest In Arvinas, Absci IPO Benzinga

Jul 13, 2021

05:20PM EDT These 3 New Biotechs Have Differentiated Platforms, Technology: BofA Benzinga

10:13AM EDT Benzinga's Top Ratings Upgrades, Downgrades For July 13, 2021 Benzinga

09:26AM EDT UPDATE: Morgan Stanley On Cyteir Therapeutics Overweight Initiation: Initial CYT-0851 Phase Data Have Been Encouraging In A Heavily-Penetrated Population, With Responses Observed In multiple Tumor Types While Maintaining A Favorable Safety Profile Benzinga

08:20AM EDT Wedbush Initiates Coverage On Cyteir Therapeutics with Outperform Rating, Announces Price Target of $40 Benzinga

07:51AM EDT Morgan Stanley Initiates Coverage On Cyteir Therapeutics with Overweight Rating, Announces Price Target of $33 Benzinga

07:45AM EDT 07:44 Tuesday, July 13, 2021Wedbush (RTTNews) - Wedbush Starts Cytec Industries Inc (CYT) At Outperform With $40 Price Target RTTNews

06:19AM EDT B of A Securities Initiates Coverage On Cyteir Therapeutics with Buy Rating, Announces Price Target of $23 Benzinga

05:27AM EDT JP Morgan Initiates Coverage On Cyteir Therapeutics with Overweight Rating, Announces Price Target of $30 Benzinga

Jul 1, 2021

08:07AM EDT The Daily Biotech Pulse: Spero Spikes On Pfizer Investment, FDA Nod For Jazz, Orchard Signs Licensing Deal, Acumen Pharma Debuts Benzinga

Jun 22, 2021

05:00PM EDT Cyteir Therapeutics Announces Closing of Initial Public Offering Business Wire

Jun 18, 2021

12:38PM EDT Cyteir Therapeutics Shares Open For Trade At $16.50; IPO Priced At $18/Share Benzinga

10:42AM EDT Cyteir Therapeutics Shares Indicating $23.40 On 83K Shares Benzinga

09:28AM EDT Cyteir Therapeutics Shares Will Open For Quote At 10:35 a.m. EDT, Expected To Open For Trade After 10:45 a.m. EDT; IPO Priced At $18/Share Benzinga

Jun 17, 2021

10:23PM EDT Cyteir Therapeutics Inc. (CYT) said that it has priced its initial public offering of 7.40 million shares of its common stock at price of $18.00 per share. RTTNews

07:15PM EDT Cyteir Therapeutics Announces Pricing of Initial Public Offering Business Wire

Share